Adamis Pharmaceuticals is a specialty biopharmaceutical company based in San Diego, California, that focuses on developing and commercializing products in the therapeutic areas of allergy, respiratory diseases, oncology, and immunology. The company is known for its product candidates, including Symjepi, a pre-filled syringe for emergency treatment of acute allergic reactions like anaphylaxis, and various inhalers for asthma treatment, such as fluticasone and beclomethasone. Additionally, Adamis is developing naloxone injection products aimed at treating opioid overdoses and offers a range of other pharmaceuticals, including corticosteroids, hormone replacement therapies, and veterinary products. The company aims to provide low-cost therapeutic alternatives in its various therapeutic pipelines, including a novel cancer vaccine and drug candidates targeting prostate cancer.
U.S. Compounding, Inc., based in Conway, Arkansas, operates as a 503B outsourcing facility and compounding-only pharmacy. The company specializes in providing compounded medications, which include sterile dosage forms, injectables, ophthalmic preparations, bioidentical hormone replacement therapies, topical compounds for pain, and veterinary products. Its clientele consists of patients, physician clinics, hospitals, and surgery centers, as well as veterinary patients, ensuring a diverse range of tailored medication solutions to meet specific health needs.
Cellegy Pharmaceuticals
Acquisition in 2008
Cellegy Pharmaceuticals operates as a specialty biopharmaceutical company.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.